TVARDI THERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable, Related Parties
TVARDI THERAPEUTICS, INC. (TVRD) reported Increase (Decrease) in Accounts Receivable, Related Parties of $822.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties · last filed 2025-05-13
- TVARDI THERAPEUTICS, INC. increase (decrease) in accounts receivable, related parties for the quarter ending 2025-03-31 was $822.00K.
- TVARDI THERAPEUTICS, INC. increase (decrease) in accounts receivable, related parties for the quarter ending 2024-12-31 was -$28.00K.
- TVARDI THERAPEUTICS, INC. increase (decrease) in accounts receivable, related parties for the quarter ending 2024-09-30 was $76.00K.
- TVARDI THERAPEUTICS, INC. increase (decrease) in accounts receivable, related parties for the quarter ending 2024-06-30 was -$1.36M, a 133.49% decline year-over-year.
- TVARDI THERAPEUTICS, INC. increase (decrease) in accounts receivable, related parties for fiscal 2024 was -$2.36M.
- TVARDI THERAPEUTICS, INC. increase (decrease) in accounts receivable, related parties for fiscal 2023 was -$495.00K, a 115.18% decline from fiscal 2022.
- TVARDI THERAPEUTICS, INC. increase (decrease) in accounts receivable, related parties for fiscal 2022 was $3.26M.
| Period end | Increase (Decrease) in Accounts Receivable, Related Parties 3 month | Increase (Decrease) in Accounts Receivable, Related Parties 6 month | Increase (Decrease) in Accounts Receivable, Related Parties 9 month | Increase (Decrease) in Accounts Receivable, Related Parties 12 month |
|---|---|---|---|---|
| 2025-03-31 | $822.00K 10-Q · filed 2025-05-13 | $794.00K derived: sum of 2 quarters · filed 2025-05-13 | $870.00K derived: sum of 3 quarters · filed 2025-05-13 | -$489.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | -$28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $48.00K derived: sum of 2 quarters · filed 2025-03-11 | -$1.31M derived: sum of 3 quarters · filed 2025-03-11 | -$2.36M 10-K · filed 2025-03-11 |
| 2024-09-30 | $76.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$1.28M derived: sum of 2 quarters · filed 2024-11-14 | -$2.33M 10-Q · filed 2024-11-14 | -$2.92M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-06-30 | -$1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$2.41M 10-Q · filed 2024-08-14 | -$2.99M derived: sum of 3 quarters · filed 2025-05-13 | -$9.77M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-03-31 | -$1.05M 10-Q · filed 2025-05-13 | -$1.63M derived: sum of 2 quarters · filed 2025-05-13 | -$8.41M derived: sum of 3 quarters · filed 2025-05-13 | -$4.35M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$586.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$7.36M derived: sum of 2 quarters · filed 2025-03-11 | -$3.30M derived: sum of 3 quarters · filed 2025-03-11 | -$495.00K 10-K · filed 2025-03-11 |
| 2023-09-30 | -$6.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$2.71M derived: sum of 2 quarters · filed 2024-11-14 | $91.00K 10-Q · filed 2024-11-14 | -$6.27M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $4.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $6.86M 10-Q · filed 2024-08-14 | $501.00K derived: sum of 3 quarters · filed 2025-03-11 | $2.12M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $2.81M 10-Q · filed 2024-05-13 | -$3.56M derived: sum of 2 quarters · filed 2025-03-11 | -$1.94M derived: sum of 3 quarters · filed 2025-03-11 | $3.57M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | -$6.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$4.74M derived: sum of 2 quarters · filed 2025-03-11 | $764.00K derived: sum of 3 quarters · filed 2025-03-11 | $3.26M 10-K · filed 2025-03-11 |
| 2022-09-30 | $1.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $7.13M derived: sum of 2 quarters · filed 2023-11-13 | $9.62M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $5.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $8.00M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $2.50M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |